AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16443418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration for 12 hours before contrast exposure, followed by hemofiltration for 18 to 24 hours after contrast exposure (post‐hemofiltration group; n = 31)
Number of subjects: 92
Study 16443418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration performed for 6 hours before and for 18 to 24 hours after contrast exposure (pre/post‐hemofiltration group; n = 31)
Number of subjects: 92
Study 16443418 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration with isotonic saline (1 mL x kg x h for 12 hours before and after contrast exposure, control group; n = 30)
Number of subjects: 92
Study 14980556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (dopaminergic drug treatment)
Number of subjects: 0
Study 11816626 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 19
Study 11816626 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 19
Study 11816626 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 19
Study 9273190 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy with daily doses of carboplatin (20 to 25 mg/m2/d over 45 or 10 min) and accelerated chest irradiation (60 to 64 Gy over 4 weeks, 2 Gy per fraction)
Number of subjects: 15
Study 9273190 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy with daily doses of carboplatin and accelerated chest irradiation
Number of subjects: 15
Study 8487562 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardioplegia
Number of subjects: 53
Study 8487562 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegia
Number of subjects: 53
Study 3306068 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg per day
Number of subjects: 0
Study 3306068 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 300 mg per day
Number of subjects: 0
Study 29362255 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme using Physitrack (online exercise prescription tool) for 8 weeks
Number of subjects: 58
Study 29362255 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme without Physitrack for 8 weeks
Number of subjects: 58
Study 27038608 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (3 mg/kg)
Number of subjects: 606
Study 27038608 — intervention group
Group type: COMPARATOR
Intervention: RP (3 mg/kg)
Number of subjects: 606
Study 26686362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Gy radiation prescribed to primary tumour
Number of subjects: 36
Study 26686362 — intervention group
Group type: COMPARATOR
Intervention: No radiation prescribed to primary tumour
Number of subjects: 36
Study 23052751 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery protocols including early laparoscopic cholecystectomy, restrictive endoscopic intervention, and early oral nutrition
Number of subjects: 60
Study 23052751 — intervention group
Group type: COMPARATOR
Intervention: Traditional recovery (TR) protocols
Number of subjects: 60
Study 19947898 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg quercetin/day with 125 mg vitamin C/day
Number of subjects: 1002
Study 19947898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg quercetin/day with 250 mg vitamin C/day
Number of subjects: 1002
Study 19947898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 20428412 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg once daily
Number of subjects: 330
Study 20428412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 16386400 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial questions from the physician during the medical interview
Number of subjects: 54
Study 16386400 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical interview with physicians varying their communication
Number of subjects: 54
Study 12809836 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg p.o. t.i.d. for 4 weeks
Number of subjects: 16
Study 12809836 — intervention group
Group type: COMPARATOR
Intervention: Placebo p.o. t.i.d. for 4 weeks
Number of subjects: 16
Study 10397378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 600 mg clomethiazole edisylate (390 mg clomethiazole base)
Number of subjects: 10
Study 10397378 — intervention group
Group type: COMPARATOR
Intervention: Rectal administration of 600 mg clomethiazole edisylate (390 mg clomethiazole base)
Number of subjects: 10
Study 10397378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 600 mg clomethiazole edisylate
Number of subjects: 10
Study 10397378 — intervention group
Group type: COMPARATOR
Intervention: Rectal administration of 600 mg clomethiazole edisylate
Number of subjects: 10
Study 10397378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and rectal administration of 600 mg clomethiazole edisylate
Number of subjects: 10
Study 8724944 — intervention group
Group type: EXPERIMENTAL
Intervention: Method based on reintroduction of letter forms (visual and verbal explanation)
Number of subjects: 38
Study 8724944 — intervention group
Group type: COMPARATOR
Intervention: Method based on copying exercises
Number of subjects: 38
Study 1874487 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin fraction 5 or thymosin‐alpha 1
Number of subjects: 12
Study 1874487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6630111 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid with probenecid
Number of subjects: 0
Study 6630111 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin alone
Number of subjects: 0
Study 31869656 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based treatment
Number of subjects: 110
Study 31869656 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 110
Study 30161238 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred choice of housing (staying at home)
Number of subjects: 79
Study 30161238 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual choice of housing
Number of subjects: 79
Study 30161238 — intervention group
Group type: EXPERIMENTAL
Intervention: Role in decision-making
Number of subjects: 79
Study 30161238 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional conflict score
Number of subjects: 79
Study 30161238 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision regret score
Number of subjects: 79
Study 26720730 — intervention group
Group type: EXPERIMENTAL
Intervention: Words presentation format
Number of subjects: 775
Study 26720730 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers presentation format
Number of subjects: 775
Study 26720730 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers plus narrative presentation format
Number of subjects: 775
Study 26720730 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers plus framed presentation format
Number of subjects: 775
Study 26720730 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 775
Study 25366886 — intervention group
Group type: EXPERIMENTAL
Intervention: Short CPR instructions via phone with continuous advice until emergency services arrived (Group 1)
Number of subjects: 119
Study 25366886 — intervention group
Group type: EXPERIMENTAL
Intervention: Short CPR instructions via phone, call terminated after information provided (Group 2)
Number of subjects: 119
Study 25366886 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to start CPR only (Group 3)
Number of subjects: 119
Study 21796410 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (30 min, 80 Hz, 150 μs)
Number of subjects: 22
Study 21796410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same protocol without electrical output)
Number of subjects: 22
Study 19520440 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model
Number of subjects: 74
Study 19520440 — intervention group
Group type: COMPARATOR
Intervention: Traditional model
Number of subjects: 74
Study 18579924 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic infrared energy treatment (1.5 J/cm(2)/min at 890 nm)
Number of subjects: 18
Study 18579924 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (no energy delivered)
Number of subjects: 18
Study 18579924 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active and sham treatments
Number of subjects: 18
Study 18579924 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic infrared energy treatment
Number of subjects: 18
Study 16007595 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific dosage and duration not provided)
Number of subjects: 65
Study 12401632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 15-45 micro g
Number of subjects: 110
Study 12401632 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 110
Study 10667283 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) at 1.6 mg/kg/day
Number of subjects: 25
Study 10667283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7599771 — intervention group
Group type: EXPERIMENTAL
Intervention: Caremap management
Number of subjects: 251
Study 7599771 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 251
Study 2082953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine‐LC (1 mg orally three times daily for 24 weeks)
Number of subjects: 80
Study 2082953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 795609 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% alcoholic solution of clobetasol propionate
Number of subjects: 40
Study 795609 — intervention group
Group type: COMPARATOR
Intervention: 0.05% alcoholic solution of betamethasone-17,21-dipropionate
Number of subjects: 40
Study 30654808 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) 4 mg/kg/day for 4 days followed by dihydroartemisinin (DHA) 2.2 mg/kg and piperaquine (PPQ) 18 mg/kg daily for 3 days
Number of subjects: 43
Study 30654808 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (AM) 1.7 mg/kg and lumefantrine (LUM) 12 mg/kg twice daily for 3 days
Number of subjects: 43
Study 30654808 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) total 25 mg/kg over 3 days
Number of subjects: 43
Study 27605986 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal corticotomy
Number of subjects: 15
Study 27605986 — intervention group
Group type: COMPARATOR
Intervention: Control (no buccal corticotomy)
Number of subjects: 15
Study 24838476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/d)
Number of subjects: 159
Study 24838476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 22623468 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide dressing (Group A)
Number of subjects: 70
Study 22623468 — intervention group
Group type: COMPARATOR
Intervention: No intracanal medication (Group B)
Number of subjects: 70
Study 20094818 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaJet® System (PJS)
Number of subjects: 60
Study 20094818 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar electrocautery
Number of subjects: 60
Study 18528751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1010
Study 18528751 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1010
Study 16006029 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 10-80 mg/day
Number of subjects: 128
Study 16006029 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylcitalopram (DCIT)
Number of subjects: 128
Study 16006029 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) and Desmethylcitalopram (DCIT) combined
Number of subjects: 128
Study 16006029 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT)
Number of subjects: 128
Study 12960461 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and whole brain radiotherapy for single brain metastasis
Number of subjects: 0
Study 12960461 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Number of subjects: 0
Study 12960461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 12960461 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 11169347 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (lignocaine 1% injected subcutaneously)
Number of subjects: 220
Study 11169347 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 220
Study 2051429 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene (Prolene)
Number of subjects: 100
Study 2051429 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS)
Number of subjects: 100
Study 6341261 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TS)
Number of subjects: 21
Study 6341261 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 21
Study 30938914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 120
Study 30938914 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 120
Study 29426035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment (CAST + cognitive bias modification)
Number of subjects: 74
Study 29426035 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 74
Study 27194552 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG, 1-3 visits first year, n=87)
Number of subjects: 180
Study 27194552 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up schedule group (CSG, 4 visits first year, n=93)
Number of subjects: 180
Study 27194552 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CSG and ESG)
Number of subjects: 180
Study 27194552 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG)
Number of subjects: 180
Study 24721481 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute computerized brief motivational intervention (C‐BMI) plus access to free nicotine replacement therapy (NRT)
Number of subjects: 0
Study 24721481 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group plus NRT access
Number of subjects: 0
Study 22293664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity human simulation
Number of subjects: 0
Study 22293664 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized interview
Number of subjects: 0
Study 22293664 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PBL (mPBL)
Number of subjects: 0
Study 20811917 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg fentanyl
Number of subjects: 60
Study 20811917 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl
Number of subjects: 60
Study 20811917 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study 18076804 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide combined with dexamethasone (TD group)
Number of subjects: 39
Study 18076804 — intervention group
Group type: COMPARATOR
Intervention: VAD regimen (vindesine, adriamycin, and dexamethasone) (VAD group)
Number of subjects: 39
Study 18076804 — intervention group
Group type: COMPARATOR
Intervention: VAD regimen (VAD group)
Number of subjects: 39
Study 15780701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, 50-150 mg/day, continuous dosing throughout the menstrual cycle
Number of subjects: 0
Study 15780701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, 50-100 mg/day, intermittent dosing for 14-16 days prior to menses
Number of subjects: 0
Study 15780701 — intervention group
Group type: COMPARATOR
Intervention: Sertraline, abruptly discontinued at onset of menses
Number of subjects: 0
Study 15780701 — intervention group
Group type: COMPARATOR
Intervention: Placebo, abruptly discontinued at onset of menses
Number of subjects: 0
Study 12523875 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 120
Study 12523875 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 120
Study 9801961 — intervention group
Group type: EXPERIMENTAL
Intervention: High anxiety sensitivity individuals
Number of subjects: 396
Study 9801961 — intervention group
Group type: COMPARATOR
Intervention: Low anxiety sensitivity individuals
Number of subjects: 396
Study 7717557 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide
Number of subjects: 26
Study 7717557 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 26
Study 1957836 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone acetic acid (FAA) at 5,120 and 6,144 mg/m2 as 3-hour intravenous infusions
Number of subjects: 17
Study 1957836 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone acetic acid (FAA) at 10,000, 12,500, 15,000, and 17,500 mg/m2 delivered in a 24-hour constant infusion
Number of subjects: 17
Study 1957836 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone acetic acid (FAA)
Number of subjects: 17
Study 7223659 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol, once daily for 1 month
Number of subjects: 23
Study 7223659 — intervention group
Group type: COMPARATOR
Intervention: 40 mg propranolol, four times daily for 1 month
Number of subjects: 23
Study 7223659 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol, once daily
Number of subjects: 23
Study 7223659 — intervention group
Group type: COMPARATOR
Intervention: 40 mg propranolol, four times daily
Number of subjects: 23
Study 31648138 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavior therapy for alcohol use disorder
Number of subjects: 138
Study 29890543 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromegaly related PTC (APTC)
Number of subjects: 19
Study 29890543 — intervention group
Group type: COMPARATOR
Intervention: Normal PTC
Number of subjects: 19
Study 29890543 — intervention group
Group type: COMPARATOR
Intervention: Multinodular goiter (MNG)
Number of subjects: 19
Study 29890543 — intervention group
Group type: COMPARATOR
Intervention: PTC without acromegaly
Number of subjects: 19
Study 29890543 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF expression in APTC
Number of subjects: 19
Study 28678307 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 70
Study 28678307 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 70
Study 26527251 — intervention group
Group type: EXPERIMENTAL
Intervention: Versapoint bipolar electrode
Number of subjects: 102
Study 26527251 — intervention group
Group type: COMPARATOR
Intervention: Diode Laser
Number of subjects: 102
Study 24161338 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated lipoprotein(a) levels (Lp(a))
Number of subjects: 76880
Study 24161338 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants (rs10455872, rs3798220) and low number of KIV-2 repeats
Number of subjects: 76880
Study 24161338 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic instrumental variable analysis for Lp(a)
Number of subjects: 76880
Study 24161338 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational analysis for Lp(a)
Number of subjects: 76880
Study 22094298 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary medical treatment for advanced glaucoma
Number of subjects: 29
Study 22094298 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgical treatment for advanced glaucoma
Number of subjects: 29
Study 22094298 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 29
Study 19761838 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated killed oral cholera vaccine (1 dose)
Number of subjects: 154
Study 19761838 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated killed oral cholera vaccine (2 doses)
Number of subjects: 154
Study 17119947 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroCoil
Number of subjects: 200
Study 17119947 — intervention group
Group type: COMPARATOR
Intervention: bare platinum coils
Number of subjects: 200
Study 15339752 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed transdermal estradiol at 0.014 mg/d (n = 208)
Number of subjects: 417
Study 15339752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 209)
Number of subjects: 417
Study 11219763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile foot-discriminable symbols
Number of subjects: 38
Study 9667484 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid (PLA) membranes
Number of subjects: 25
Study 9667484 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin‐910 (PG‐910) membranes
Number of subjects: 25
Study 8004302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 15 ppm NO in air
Number of subjects: 14
Study 1968754 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol (12 micrograms)
Number of subjects: 12
Study 1968754 — intervention group
Group type: COMPARATOR
Intervention: terbutaline (250 micrograms)
Number of subjects: 12
Study 1968754 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 427003 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg twice daily
Number of subjects: 11
Study 427003 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 375 mg twice daily
Number of subjects: 11
Study 427003 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal taken on an empty stomach
Number of subjects: 11
Study 427003 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal taken with meals
Number of subjects: 11
Study 427003 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 11
Study 30970128 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation-dominant IBS (IBS-C)
Number of subjects: 115
Study 30970128 — intervention group
Group type: COMPARATOR
Intervention: Mixed-type IBS or diarrhea-dominant IBS
Number of subjects: 115
Study 28169285 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg
Number of subjects: 1394
Study 28169285 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg
Number of subjects: 1394